| Literature DB >> 30777447 |
Yung-Jue Bang1, Eric Van Cutsem2, Charles S Fuchs3, Atsushi Ohtsu4, Josep Tabernero5, David H Ilson6, Woo Jin Hyung7, Vivian E Strong8, Thorsten Oliver Goetze9, Takaki Yoshikawa10, Laura H Tang8, Peggy May Tan Hwang11, Nancy Webb11, David Adelberg11, Kohei Shitara4.
Abstract
BACKGROUND: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. AIM: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov : NCT03221426.Entities:
Keywords: adjuvant therapy; chemotherapy; gastric cancer; gastroesophageal junction cancer; immunotherapy; neoadjuvant therapy; pembrolizumab; surgery
Mesh：
Substances：
Year: 2019 PMID： 30777447 DOI： 10.2217/fon-2018-0581
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404